Microbioz India, February 2023 | 51 Biognosys and Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma and Biomarker Customers Story source/Credit: Bruker Corporation New strategic partnership aims to broaden access to Biognosys’ leading CRO services and Spectronaut® software tools for unbiased proteomics and epiproteomics ruker Corporation and Switzerland-based Biognosys AG have announced a strategic partnership, in which Bruker has made a majority-ownership investment in Biognosys. Financial details were not disclosed. J.P.Morgan acted as exclusive financial advisor to Biognosys. Several of Biognosys’ earlier investors have sold their shares to Bruker in a secondary transaction, and Bruker will make new primary investments in Biognosys. Co-Founder and CEO Dr. Oliver Rinner and his leadership team will continue to manage Biognosys as a world-leading proteomics and proteogenomics CRO services and proteomics software company. Going forward, Biognosys’ biomarker and biopharma customers will benefit from additional services and footprint in the US. Biognosys will access Bruker’s leading 4D proteomics timsTOF technology for deeper, unbiased high-precision proteomics that is not impaired by epitope crossreactivity - all with higher throughput and excellent reproducibility. Biognosys mass spectrometry-based proteomics solutions help CRO services and proteomics software customers in uncovering connections between genome, transcriptome, and phenotype to explore the static and dynamic nature of disease biology. In particular, the Biognosys TrueTarget™, TrueDiscovery™, and TrueSignature™ research service solutions provide deep, peptide-level proteome insights for drug discovery and development: TrueTarget™ uniquely addresses pressing challenges in drug discovery by identifying on- and off-target effects, and characterizing binding sites. TrueDiscovery™, powered by Spectronaut® proteomics software, offers unbiased, multidimensional insights into the expression, function, and structure of up to 4,200 proteins in plasma, up to 11,000 proteins in other biofluids, and up to 13,800 proteins in tissue or cell lines. TrueSignature™ high-precision, customizable, multiplex panels enable simultaneous absolute quantification of proteins for pharmacodynamic readouts and clinical biomarker monitoring, in support of pharmacoproteomics-enhanced clinical trials. The Bruker-Biognosys collaboration is expected to create unique synergies between Biognosys’ versatile portfolio of proprietary proteomics services, software and kits, and Bruker’s pioneering timsTOF platform. As a result of the strategic partnership, Biognosys plans to open its first advanced proteomics CRO services laboratory in the United States. Dr. Oliver Rinner, CEO and Co-Founder of Biognosys, commented: "We are pleased to partner with Bruker to leverage our unique synergies to enable customers to explore the depth of the proteome from early research to clinical development. We have worked closely with Bruker to support dia-PASEF® high-throughput, deeper proteomics methods within our Spectronaut® software. Biognosys remains committed to maintaining Spectronaut® as a high-performance vendor-agnostic proteomics software. We plan to establish our US CRO lab in Massachusetts using the timsTOF platform, so that our customers can benefit from multiple MS technologies.” Dr. Rohan Thakur, President of the Bruker LifeScience Mass Spectrometry division, said: “We are delighted to partner with Biognosys to expand our CRO business in the US. B Product Launches
Microbioz India, February 2023 | 52 We have many common biomarker and biopharma customers, and even more potential customers may prefer a proteomics CRO services expert like Biognosys for rapid, highest quality and flexible insertion of proteomics into their biomarker or biopharma discovery and development. With the rapid scientific acceptance of dia-PASEF workflows, our partnership offers a unique combination of proteomics applications and datascience expertise, which can benefit more biopharma and diagnostics companies in using unbiased proteomics for decision-making.” Professor emeritus and proteomics pioneer Dr. Ruedi Aebersold added: “For over a decade, ETH spin-off Biognosys has translated novel proteomics methods pioneered in our research group into robust, high-performance workflows for large-scale basic and translational research. I am delighted that this new partnership between Biognosys and Bruker will further accelerate access to high performance proteomics. It will also provide opportunities to develop next-generation technology and methods to determine unexplored but functionally relevant dimensions of the proteome, such as the modulation of proteoform composition, and protein interaction networks as a function of cellular state.” About Biognosys AG At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers, biomarker and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary nextgeneration proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship proteomics software Spectronaut®. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for biomarker and biopharma R&D, development and translational research. About Bruker Corporation Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, highvalue life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. DermTech’s Melanoma Assay Gets VHA Recommendation Story source/Credit: Derm Tech ermTech, a provider in precision dermatology enabled by a non-invasive skin genomics platform, announced that U.S. General Services Administration has recommended the company’s foundational assay included in the DermTech Melanoma Test (DMT) for coverage by the Veterans Health Administration (VHA). This coverage recommendation makes the foundational assay of the DMT available to the VHA’s over 9 million enrolled Veterans. D Product Launches
Microbioz India, February 2023 | 53 The DMT is a non-invasive way to enhance melanoma detection with a greater than 99% negative predictive value (NPV), according to the company. The VHA provides care at 1,298 healthcare facilities across the United States. “We’re honored to join the VHA in bringing our non-invasive melanoma test to America’s Veterans,” says Dan Visage, senior vice president of payor access, DermTech. “The DMT test results are clinically meaningful and actionable, improve patient care and reduce healthcare costs. We look forward to teaming up with the VHA to make our test widely available to its beneficiaries in the coming months.” DermTech’s total covered lives in the U.S. are now approximately 124 million, which includes 68 million for Medicare/Medicare Advantage and 56 million for commercial and governmental payers. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. Featured image: Melanoma Mylab and Qure.ai join hands for Tuberculosis Screening Solutions Qure.ai will provide the AI-interpretation engine for Mylab’s upcoming radiology devices Story source/Credit: Mylab Discovery Solutions ylab Discovery Solutions, India’s leading biotech company, today announced its partnership with Qure.ai, a leading provider of artificial intelligence (AI) software, for medical imaging, to deploy AI technology-enabled chest X-ray for early detection of tuberculosis (TB) and aid in universal lung health. Under the partnership, Mylab’s soon-to-be launched handheld X-Ray device, MyBeam will leverage Qure.ai’s cutting-edge AI software, qXR, to improve the accuracy and speed of TB diagnosis. MyBeam in conjunction with qXR will be an effective screening tool for TB detection and will help improve access to TB testing. The collaboration will be a key accelerator in the country’s mission to screen and detect patients for pulmonary TB and support the Government of India’s agenda to eliminate TB by 2025. The implementation of the AI-enabled Chest X-Ray solutions for TB screening will strengthen access to screening among populations who are at greater risk for this disease. Speaking about the partnership, Hasmukh Rawal, MD & Co-founder, Mylab Discovery Solutions, said, “Mylab is distinctly positioned to serve the need of TB program of India with the most comprehensive portfolio of solutions for screening, detection and prevention. Our hand-held X-ray device will strengthen our TB screening capabilities and with Qure.ai’s power of deep learning for radiology, the process will become much faster, more objective and scalable. It is a perfect example of two home grown companies coming together to M contribute towards nation’s health.” Product Launches
Microbioz India, February 2023 | 54 Commenting on the partnership, Prashant Warier, Co-founder and CEO, Qure.ai, said; “The partnership with Mylab comes at a very significant time. Both companies are leading healthcare players from India, making significant strides towards the common goal of TB elimination. Our AI-enabled integrated portable X-ray device is a scalable solution and an ideal example of how technology can make a difference in the lives of millions” MyBeam, India’s first portable X-Ray device, through its investee company Lipomic, is equipped with state-of-the-art high-frequency technology. It is the latest addition to Mylab’s suite of solutions for screening, detection and prevention of TB. The device offers high performance and greater speed as it acquires images within a few minutes. It’s extremely compact, lightweight and provides expanded clinical coverage. It can be used at resource-limited settings or where there’s a lack of access to equipment. MyBeam will prove to be extremely beneficial for finding TB cases in the most remote settings. qXR for TB is a cutting-edge AI software that uses deep learning algorithms to analyse chest X-rays and accurately identify TB under a minute. qXR is WHO recommended and CE class II certified to be used for preliminary TB screening and gives its interpretation in under a minute. Qure.ai’s lung health suite of products will complement the existing screening and diagnostic pathways and enable a sustained increase in active case findings. India remains the highest contributor to global TB cases, accounting for 26 per cent of total cases and 34 per cent of all deaths worldwide. Annual TB cases in India rose by 19% in 2021 and TB deaths recorded a 11% per cent hike in 2021 from the previous year, as per the India TB report 2022. Still, there remains a large gap between the estimated incidence and the number TB cases reported. Early and accurate diagnosis is critical to effective treatment and disease control. The partnership will have MyBeam integrated with Qure.ai’s AI-enabled computer-assisted detection software, along with its lung health management platform, to evaluate chest X-rays and identify presumptive TB patients. The AI-enabled screening pathway will be crucial for augmenting the current TB screening mechanism and alleviate pressure on the healthcare workforce relative to identification of TB presumptive patients. Product Launches
Microbioz India, February 2023 | 55
Microbioz India, February 2023 | 56 PUBLISHED ON: 25th February 2023 RNI NUMBER: UPENG/2017/73675